Vericel (VCEL) Receivables (2010 - 2026)
Vericel (VCEL) posted Receivables of $75.7 million for Q2 2026, up 4.6% sequentially from $72.4 million in Q1 2026, and up 17.77% YoY from $64.3 million in Q2 2025.
Vericel (VCEL) Receivables (2010 - 2026) Analysis & Trends
Vericel has reported Receivables for 17 years, with the latest figure at $75.7 million in Q2 2026.
- Quarterly Receivables rose 17.77% year-over-year to $75.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $75.7 million (up 17.77% YoY) and the FY2025 annual result came in at $84.6 million, up 37.9% from the prior year.
- Receivables rose to $75.7 million in Q2 2026 per VCEL's latest filing, from $72.4 million in the prior quarter.
- Over five years, Receivables peaked at $84.6 million in Q4 2025 and troughed at $31.9 million in Q1 2022.
- A 5-year average of $52.2 million and a median of $49.2 million in 2024 frame the typical range for Receivables.
- The sharpest annual moves came in 2024 and 2025: Receivables increased 5.17% in 2024, then jumped 37.9% in 2025.
- Over 5 years, Receivables stood at $46.5 million in 2022, then rose by 25.39% to $58.4 million in 2023, then gained by 5.17% to $61.4 million in 2024, then jumped by 37.9% to $84.6 million in 2025, then retreated by 10.54% to $75.7 million in 2026.
- According to Business Quant data, Receivables over the past three periods registered $75.7 million, $72.4 million, and $84.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.93 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.06 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.84 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 912.74 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Vericel | 2.26 Bn | 2.10 Bn | 56.40 Mn | 75.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 75.71 Mn |
| Mar 31, 2026 | 72.38 Mn |
| Dec 31, 2025 | 84.63 Mn |
| Sep 30, 2025 | 60.43 Mn |
| Jun 30, 2025 | 64.29 Mn |
| Mar 31, 2025 | 52.90 Mn |
| Dec 31, 2024 | 61.38 Mn |
| Sep 30, 2024 | 48.48 Mn |
| Jun 30, 2024 | 48.00 Mn |
| Mar 31, 2024 | 49.93 Mn |
| Dec 31, 2023 | 58.36 Mn |
| Sep 30, 2023 | 39.73 Mn |
| Jun 30, 2023 | 38.32 Mn |
| Mar 31, 2023 | 38.36 Mn |
| Dec 31, 2022 | 46.54 Mn |
| Sep 30, 2022 | 34.30 Mn |
| Jun 30, 2022 | 33.66 Mn |
| Mar 31, 2022 | 31.86 Mn |
| Dec 31, 2021 | 37.44 Mn |
| Sep 30, 2021 | 28.91 Mn |